Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Zenicor Medical Systems AB's ROE % or its related term are showing as below:
XSAT:ZENI'
s ROE % Range Over the Past 10 Years
Min: -54.77 Med: -10.18 Max: 8.54
Current: 1.87
During the past 13 years, Zenicor Medical Systems AB's highest ROE % was 8.54%. The lowest was -54.77%. And the median was -10.18%.
XSAT:ZENI's ROE % is ranked worse than 52.26% of 798
companies
in the Medical Devices & Instruments industry
Industry Median: 2.51
vs XSAT:ZENI: 1.87
Zenicor Medical Systems AB (XSAT:ZENI) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Zenicor Medical Systems AB's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zenicor Medical Systems AB ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zenicor Medical Systems AB's ROE % distribution charts can be found below:
* The bar in red indicates where Zenicor Medical Systems AB's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Zenicor Medical Systems AB (XSAT:ZENI) has a ROE % of 1.16% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Zenicor Medical Systems AB and its competitors. According to the industry distribution chart, Zenicor Medical Systems AB ranks #417 out of 798 companies in the Medical Devices & Instruments industry, placing it in the top 52.3%.
Is Zenicor Medical Systems AB's ROE % too high?
Zenicor Medical Systems AB's current ROE % is 1.16%. The Medical Devices & Instruments industry median ROE % is 2.51. Zenicor Medical Systems AB's value of 1.16% is 53.8% below this industry median. Based on the distribution chart, Zenicor Medical Systems AB ranks #417 out of 798 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Zenicor Medical Systems AB has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zenicor Medical Systems AB's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Zenicor Medical Systems AB ranks #417 out of 798 companies for ROE %. This places Zenicor Medical Systems AB in the lower half of its industry. The industry median ROE % is 2.51. Zenicor Medical Systems AB's value of 1.16% is 53.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.51, based on 798 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zenicor Medical Systems AB's current ROE % of 1.16% is 53.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Zenicor Medical Systems AB and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zenicor Medical Systems AB's current ROE % is 1.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenicor Medical Systems AB stock overvalued right now?
Based on GuruFocus' analysis, Zenicor Medical Systems AB (XSAT:ZENI) is currently considered Modestly Undervalued. The stock's GF Value™ is kr1.32, compared to a current price of kr0.95 — trading 28% below its estimated fair value. The current ROE % is 1.16% and 53.8% below the Medical Devices & Instruments industry median of 2.51. Zenicor Medical Systems AB's overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Zenicor Medical Systems AB (XSAT:ZENI), the current ROE % is 1.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zenicor Medical Systems AB (XSAT:ZENI) Overvalued in 2026?
Based on GuruFocus' analysis, Zenicor Medical Systems AB stock appears to be undervalued.
The current stock price of kr0.95 is trading 28% below its estimated GF Value™ of kr1.32.
GuruFocus considers Zenicor Medical Systems AB to be Modestly Undervalued.
Key valuation signals for XSAT:ZENI:
ROE %: 1.16%
GF Value™: kr1.32 vs. price of kr0.95 (28% below fair value)
Industry Position: 53.8% below the Medical Devices & Instruments median (#417 of 798)
No single metric tells the full story. See the XSAT:ZENI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:ZENI has been successfully added to your 
